Quantitative analysis of bortezomib-induced IL-8 gene expression in ovarian cancer cells.
Quantitative analysis of bortezomib-induced IL-8 gene expression in ovarian cancer cells.
复制标题
硼替佐米诱导的卵巢癌细胞中 IL-8 基因表达的定量分析。
DOI：
10.1007/978-1-4939-0928-5_27
复制
发表时间：
2014
期刊：
影响因子：
--
通讯作者：
Vancurova,Ivana
中科院分区：
文献类型：
--
作者：
Singha,Bipradeb;Phyo,SaiA;Gatla,HimavanthR;Vancurova,Ivana
白介素 8 (IL-8) 最初被发现是中性粒细胞趋化剂和白细胞介导的炎症诱导剂，通过诱导肿瘤细胞增殖、存活和迁移而促进癌症进展。 IL-8 表达在多种类型的晚期癌症中增加，包括卵巢癌，并与不良预后相关。硼替佐米 (BZ) 是 FDA 批准的第一个蛋白酶体抑制剂，在多发性骨髓瘤和其他血液恶性肿瘤中显示出显着的抗肿瘤活性。在包括卵巢癌在内的实体瘤中，BZ 作为单一药物的效果较差。然而，其机制仍然未知。我们最近发现，在卵巢癌细胞中，BZ 大大增加了 IL-8 的表达，而其他 NFκB 调节的细胞因子 IL-6 和 TNF 的表达却没有变化。在本章中，我们描述了一种使用实时 qRT-PCR 定量分析 BZ 处理的卵巢癌细胞中 IL-8 和 IL-6 mRNA 水平的方案。该方案可以轻松修改并用于分析不同细胞类型中的其他细胞因子。
Interleukin-8 (IL-8), originally discovered as the neutrophil chemoattractant and inducer of leukocyte-mediated inflammation, contributes to cancer progression through its induction of tumor cell proliferation, survival, and migration. IL-8 expression is increased in many types of advanced cancers, including ovarian cancer, and correlates with poor prognosis.Bortezomib (BZ) is the first FDA-approved proteasome inhibitor that has shown remarkable antitumor activity in multiple myeloma and other hematological malignancies. In solid tumors, including ovarian carcinoma, BZ has been less effective as a single agent; however, the mechanisms remain unknown. We have recently shown that in ovarian cancer cells, BZ greatly increases IL-8 expression, while expression of other NFκB-regulated cytokines, IL-6 and TNF, is unchanged. In this chapter, we describe a protocol that uses real-time qRT-PCR to quantitatively analyze mRNA levels of IL-8 and IL-6 in BZ-treated ovarian cancer cells. The protocol can be easily modified and used for analysis of other cytokines in different cell types.